2008-07-23 20:40:01 -
www.researchandmarkets.com - Research and Markets (www.researchandmarkets.com/research/b0eecf/south_africa_pharm) has announced the addition of the "South Africa Pharmaceuticals and Healthcare Report Q3 2008" report to their offering.
South Africa Pharmaceuticals and Healthcare Report provides independent forecasts and competitive intelligence on South Africa's pharmaceuticals and healthcare industry.
South Africa's pharmaceutical and healthcare markets are
going through a period of regulatory upheaval. On the approvals front, a new South African Health Products Regulatory authority has been proposed to replace the Medicines Control Council (MCC); on the pricing front, the government has drafted plans to more strictly regulate private hospital prices; and on the business environment front, the South African Healthcare Charter sets out guidelines for Black Economic Empowerment (BEE). Despite the upheavals, South Africa's pharmaceutical market remains one of the most promising in Africa. BMI estimates that the market was worth US$3.03bn in 2007 and it should reach US$4.41bn by 2012. The drug market should continue to grow head of inflation despite controls limiting pharmaceutical price rises, indicating that there will be significant volume growth in the market.
This view is reflected in our updated Business Environment Rankings for Q308. South Africa remains in third position out of 13 countries surveyed in the Middle East & Africa thanks to its large market and strong growth prospects. South Africa's score is held back by a slow approvals process. Under the present system it can take 24-36 months to register a pharmaceutical. However, the proposed regulatory overhaul aims to cut this to 12 months for a new chemical entity (NCE).
The local pharmaceutical industry is relatively strong in spite of regulatory challenges and competition from multinationals. Parent company Tiger Brands continues to hold plans to spin off its pharmaceutical interest Adcock Ingram through a separate listing on the Johannesburg stock exchange (JSE). However, this has been delayed by Adcock Ingram's naming in an investigation by the Competition Commission into allegations of price fixing in government hospital tenders.
The results of South Africa's new HIV/AIDS drug tender are due to be announced in Q308. The main criteria for winning a slice of the contract remains price. However, a local manufacturing presence and black empowerment policy will also play a part in the decision.
Healthcare funding remains a key issue in South Africa. Despite significant increases in the Department of Health's budget (expected to be 10% a year to 2010), the affordability of the fight against HIV/AIDS remains a concern. Meanwhile, private healthcare costs are expected to be more strictly regulated as the government looks to encourage more people into the private health insurance market.
Key Topics Covered:
"Executive Summary
South Africa Political SWOT
South Africa Economic SWOT
South Africa Business Environment SWOT
Pharmaceutical Business Environment Ratings
Table: Pharmaceutical Business Environment Ratings
Limits To Potential Returns
Risks To Realisation Of Returns
South Africa - Market Summary
Regulatory Regime
Table: South Africa Drug Classification System (Section 22A Of Medicines And Reated Substance Act 101 Of 1965)
Recent Regulatory Developments
Proposed Scope Of the South African Health products Regulatory
Intellectual Property Environment
Compulsory Licensing
Counterfeit Activity
Pricing System
Reimbursement System
Recent Pricing And Reimbursement Developments
Table: Companies Involved In South Africa's February 2008 Price Fixing Scandal
Industry Developments
Epidemiology
Table: Leading Causes Of Disease In Africa, 2002
HIV/AIDS
Tuberculosis
Healthcare Sector
Recent Healthcare Sector Developments
Health Insurance
Government Health Insurance
Recent Insurance Industry Developments
Pharmaceutical Sector
Table: PIASA Membership
ARV Manufacturing and Government Tenders
Table: Results Of South Africa's HIV/AIDS Drug Tender, March 2005
Domestic Company Developments
Key Facts: Strategic Partnership Between Strides Arcolab And Aspen Pharmacare
Foreign Company Developments
Retail Pharmacy Sector
Research And Development Sector
AIDS/HIV Research
Vaccines
Traditional African Medicine
Medical Devices
Table: South African Customs Classification Of Medical Devices
Regional Developments in Medical Devices Sector
Table: Aims Of PEPFAR-BD Partnership
Industry Forecast Scenario
Overall Market Forecast
Table: Drug Expenditure And Prescription Market Indicators (US$mn unless otherwise stated)
Key Growth Factors - Industry
Table: Health Expenditure Indicators, 2006-2012
Key Growth Factors - Macroeconomic
Table: South Africa - Economic Activity
Patented Market Forecast
Table: South Africa's Prescription Drug Market Forecast Indicators (US$mn unless otherwise stated)
Generics Market Forecast
Table: South Africa's Generic Drug Market, 2006-2012
OTC Market Forecast
Table: South Africa's OTC Drug Market Indicators, 2006-2012 (US$mn unless otherwise stated)
Medical Device Forecast
Table: South Africa's Medical Device Market, 2005-2012 (US$mn unless otherwise stated)
Export/Import Forecasts
Table: South Africa's Export And Import Trade Indicators, 2006-2012 (US$mn)
Other Healthcare Data
Table: General Healthcare Indicators, 2006-2012
Key Risks To BMI's Forecast Scenario
Competitive Landscape
Table: Top 10 Drugmakers In South Africa, 2006
Company Monitor
Leading Foreign Companies
Sanofi-Aventis
Pfizer
Roche
GlaxoSmithKline
Merck & Co
Leading Indigenous Manufacturers
Aspen Pharmacare
Adcock Ingram
Enaleni Pharmaceuticals
BMI Forecast Modelling
How We Generate Our Pharmaceutical Industry Forecasts
Pharmaceutical Business Environment Ratings Methodology
Ratings Overview
Table: Pharmaceutical Business Environment Indicators
Weighting
Table: Weighting Of Components
Sources
Companies Mentioned:
- Sanofi-Aventis
- Pfizer
- Roche
- GlaxoSmithKline
- Merck & Co
- Aspen Pharmacare
- Adcock Ingram
- Enaleni Pharmaceuticals
For more information visit
www.researchandmarkets.com/research/b0eecf/south_africa_pharm
Research and Markets
Laura Wood
Senior Manager
press@researchandmarkets.com
Fax from USA: 646-607-1907
Fax from rest of the world: +353-1-481-1716
